Santen Pharmaceutical Financials
| SNPHF Stock | USD 10.53 0.62 5.56% |
Santen |
Santen Pharmaceutical Stock Summary
Santen Pharmaceutical competes with Ono Pharmaceutical, GSK Plc, Grifols SA, and Pfizer. Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Grand Front Osaka |
| Sector | Healthcare |
| Industry | Drug Manufacturers—General |
| Benchmark | Dow Jones Industrial |
| Website | www.santen.com |
| Phone | 81 6 7664 8621 |
| Currency | USD - US Dollar |
Santen Pharmaceutical Key Financial Ratios
There are many critical financial ratios that Santen Pharmaceutical's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Santen Pharmaceutical reports annually and quarterly.| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Beta | 0.38 | |||
| Last Dividend Paid | 16.0 |
Santen Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Santen Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Santen Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Santen Pharmaceutical competition to find correlations between indicators driving Santen Pharmaceutical's intrinsic value. More Info.Santen Pharmaceutical Co is currently regarded as top stock in return on equity category among its peers. It is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Santen Pharmaceutical's earnings, one of the primary drivers of an investment's value.Santen Pharmaceutical Systematic Risk
Santen Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Santen Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Santen Pharmaceutical correlated with the market. If Beta is less than 0 Santen Pharmaceutical generally moves in the opposite direction as compared to the market. If Santen Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Santen Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Santen Pharmaceutical is generally in the same direction as the market. If Beta > 1 Santen Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
Santen Pharmaceutical December 14, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Santen Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Santen Pharmaceutical Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Santen Pharmaceutical Co based on widely used predictive technical indicators. In general, we focus on analyzing Santen Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Santen Pharmaceutical's daily price indicators and compare them against related drivers.
| Information Ratio | (0.09) | |||
| Maximum Drawdown | 15.41 | |||
| Value At Risk | (4.37) | |||
| Potential Upside | 2.7 |
Complementary Tools for Santen Pink Sheet analysis
When running Santen Pharmaceutical's price analysis, check to measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |